Landos Biopharma is a clinical-stage biopharmaceutical company that develops oral therapeutics for patients with autoimmune diseases. The company's lead products include omilancor, NX-13, and LABP-104, which are gut-restricted oral therapeutics that target LANCL2, NOD-like, and LANCL2 agonist for the treatment of UC, CD, eosinophilic esophagitis, systemic lupus erythematosus, RA, and nonalcoholic steatohepatitis. With its headquarters in Blacksburg, Virginia, the company was established in 2017.